|21 Oct 2014||davemac3||that's why the numpty is filtered read more...|
|Thu 16:15||sicker||Good old Monty, post 9664, 1265 after figures. :-) One has to smile. read more...|
|Thu 16:11||xxxxxy||http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11179961/GlaxoSmithKlines-mulled-HIV-spin-off-bigger-than-MandS-and-Sainsburys-combined.html read more...|
Why all of the silly remarks to perfectly reasonable questions about how the EPS is viewed? Crazy read more...|
|Wed 16:42||dr biotech||Firstly of course they have to get it to work. Then I'd like to seem them give it away at cost, first to the aid workers then the general population. I think really the numbers that will need it are small though.
As for the comment
"Total EPS as I see it is set to be way lower than 2013 and the PE derived puts GSK at around 22x, which is more expensive than stronger peers"
This really is... read more...|
|Wed 15:14||tradermichael||The fact of the matter is: Among stocks on the move in London, GlaxoSmithKline (GSK) climbed 3.1% after the drug maker reported third-quarter earnings that beat analysts' expectations. The company also says it expects to have the first doses of its Ebola vaccine ready late this year. read more...|
|21 Oct 2014||zzaxx99||montyhedge
10 Oct'14 - 12:41 - 9601 of 9671 1 1
Market will hit 6250, wait get these at 1335p.
10 Oct'14 - 16:36 - 9607 of 9671 2 1
P.e of GSK still far to high, figures will diasppoint, new target 1235p.
14 Oct'14 - 08:45 - 9620 of 9671 0 1
New Target 1265p, still to high.
15 Oct'14 - 18:53 - 9648 of 9671 0 1
1235p disappointing figures on they... read more...|